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A B S T R A C T
The lack of validated immunological correlates of protection makes tuberculosis vaccine development diﬃcult
and expensive. Using intradermal bacille Calmette-Guréin (BCG) as a surrogate for aerosol Mycobacterium tu-
berculosis (M.tb) in a controlled human infection model could facilitate vaccine development, but such a model
requires preclinical validation. Non-human primates (NHPs) may provide the best model in which to do this.
Cynomolgus and rhesus macaques were infected with BCG by intradermal injection. BCG was quantiﬁed from a
skin biopsy of the infection site and from draining axillary lymph nodes, by culture on solid agar and quanti-
tative polymerase chain reaction. BCG was detected up to 28 days post-infection, with higher amounts of BCG
detected in lymph nodes after high dose compared to standard dose infection. Quantifying BCG from lymph
nodes of cynomolgus macaques 14 days post-high dose infection showed a signiﬁcant reduction in the amount of
BCG detected in the BCG-vaccinated compared to BCG-naïve animals. Demonstrating a detectable vaccine eﬀect
in the lymph nodes of cynomolgus macaques, which is similar in magnitude to that seen in an aerosol M.tb
infection model, provides support for proof-of-concept of an intradermal BCG infection model and evidence to
support the further evaluation of a human BCG infection model.
1. Introduction
Tuberculosis (TB) remains an important global health threat, with
an estimated 10.4 million new cases and 1.8 million deaths in 2015 [1].
A third of the world's population are latently infected with the causative
agent, Mycobacterium tuberculosis, (M.tb) with a 10% lifetime risk of
developing active disease, which increases in those co-infected with
HIV [1]. This level of infection, combined with the emergence of
multiple and extensively drug-resistant strains ofM.tb [2], mean that an
eﬀective vaccine is an essential tool in controlling the spread of infec-
tion and reducing the burden of this disease.
Bacille Calmette-Guréin (BCG) is a live, attenuated strain of
Mycobacterium bovis (M. bovis) and the only licenced TB vaccine. BCG
confers variable levels of protection against pulmonary TB in adults,
ranging from 0 to 80% depending on geographical location [3]. The
lack of validated correlates of protection makes vaccine development
very challenging, as it is diﬃcult to predict whether a candidate vaccine
will show eﬃcacy in the target population without costly and time-
consuming eﬃcacy trials. A clinically advanced candidate vaccine,
MVA85A, showed some promising results in pre-clinical animal models
[4–6] and in early phase I/IIa safety and immunogenicity studies [7–9],
but failed to show an improvement in eﬃcacy over BCG alone in a large
scale phase IIb trial in South African infants [10]. In light of this eﬃ-
cacy data, animal models used for TB vaccine development are being re-
evaluated [11]. The use of controlled human infection models has
greatly beneﬁtted vaccine selection and development for other in-
fectious diseases [12–15]. Infecting humans with M.tb is not ethically
acceptable, but the use of intradermal (ID) BCG as a surrogate for M.tb
infection in a human mycobacterial infection model could aid in as-
sessing potential eﬃcacy at an early stage and in candidate vaccine
selection. We have previously shown that a controlled human BCG in-
fection model, where healthy adult volunteers receive BCG by
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intradermal administration into the upper arm and bacterial load is
quantiﬁed from a biopsy of the site two weeks later, can detect a re-
duction in the amount of BCG recovered in previously BCG-vaccinated
volunteers compared to those who were BCG-naïve [16,17]. Further
work has been conducted to optimise this infection model in humans,
by varying strain and dose of BCG used [18].
This ID BCG infection model has evidence of biological validity as a
surrogate for aerosol M.tb infection as both infection models have de-
monstrated a similar BCG vaccine eﬀect in mice [19]. Minassian et al.
showed that the eﬃcacy of BCG vaccination against subsequent BCG
infection of the skin in the murine model was comparable to the known
eﬃcacy of BCG against M.tb infection in the lung. In a similar BCG
infection model in cattle, Villarreal et al. demonstrated that infecting
previously BCG-vaccinated animals intranodally with BCG Tokyo
showed partial protection compared to BCG-naïve animals, paralleling
the level of BCG eﬃcacy seen with aerosol M. bovis infection [20]. Non-
human primates (NHPs) are considered to provide the most re-
presentative animal model for TB vaccine studies, due to their anato-
mical and physiological likeness to humans and similar pathology and
infection outcome [21,22]. BCG vaccination is known to be partially
protective against aerosolM.tb infection in both cynomolgus and rhesus
macaques [23,24]. Both species have been used extensively in research
into the pathogenesis ofM.tb infection and the pre-clinical evaluation of
candidate TB vaccines [22]. As it is not possible to compare an ID BCG
infection model with an aerosol M.tb infection model in humans, de-
monstration of a similar BCG vaccine eﬀect in the two models in NHPs
would bridge this gap and provide biological validation for use of this
model in humans for the evaluation of new candidate TB vaccines.
Here we present work carried out in NHPs to develop this BCG in-
fection model in cynomolgus and rhesus macaques. We started with a
study based on the design of successful early clinical trials with the BCG
infection model in humans [16,17] and then developed this model
further for use in NHPs. If validated against aerosol M.tb infection, this
BCG infection model would also provide a less expensive, less severe
method of testing candidate TB vaccines in NHPs. It would not require
the use of expensive BSL3 containment facilities and would greatly
enhance the welfare of the animals [25], in line with the ‘reﬁnement’
criteria of the National Centre for Replacement, Reﬁnement and Re-
duction of Animals in Research (NC3Rs) [26,27].
2. Methods
2.1. Experimental animals
The animals used in these studies were rhesus macaques of Indian
genotype and cynomolgus macaques of Mauritian genotype obtained
from established UK breeding colonies and were between 4 and 15
years of age. Absence of previous exposure to mycobacterial antigens
was conﬁrmed by a tuberculin skin test and screening using an ex-vivo
IFN-γ ELISpot (MabTech, Nacka. Sweden) to measure responses to
puriﬁed protein derivative (PPD) from M.tb (SSI, Copenhagen,
Denmark), and pooled 15-mer peptides of ESAT-6 and CFP-10 (Peptide
Protein Research LTD, Fareham, UK). The Project Licence enabling
these studies was approved by the Ethical Review Process of Public
Health England (PHE), Porton, Salisbury, UK and the Home Oﬃce, UK.
Animals were housed in socially compatible groups and according to
the Home Oﬃce (UK) Code of Practice for the Housing and Care of
Animals Used in Scientiﬁc Procedures (1989), (now updated to Code of
Practice for the housing and Care of Animals Bred, Supplied or Used for
Scientiﬁc Purposes, December 2014), the NC3Rs, and the Guidelines on
Primate Accommodation, Care and Use, August 2006 (NC3Rs, 2006).
For procedures requiring removal from their housing, animals were
sedated by intramuscular (IM) injection with ketamine hydrochloride
(Ketaset, 100 mg/ml, Fort Dodge Animal Health Ltd, Southampton, UK;
10 mg/kg). None of the animals had been used previously for experi-
mental procedures.
2.2. Clinical procedures
Animals were monitored daily for behavioural or clinical changes.
Prior to blood sample collection, vaccination and euthanasia, animals
were weighed, body temperature measured and were examined for
gross abnormalities.
2.2.1. BCG vaccination
Macaques were vaccinated intradermally in the upper left arm with
100 μl BCG Danish strain 1331 (SSI, Copenhagen, Denmark). BCG was
prepared and administered according to manufacturer's instructions for
preparation of vaccine for administration to human adults, by addition
of 1 ml Sauntons diluent to a vial of vaccine, to give a suspension of
BCG at an estimated concentration of 2–8 × 106 CFU/ml.
2.2.2. BCG infection
Macaques were infected intradermally in the upper right arm with
100 μl BCG Danish strain 1331 (SSI, Copenhagen, Denmark) at a con-
centration equivalent to an adult human vaccine dose (‘standard in-
fection dose’) as described above, or at a concentration 5-fold greater
(‘high infection dose’). For the high infection dose, 5 vials of BCG SSI
vaccine were reconstituted with 0.2 ml of Sauntons diluent and com-
bined to give a suspension of BCG at an estimated concentration of
1–4 × 107 CFU/ml. In each case the exact location of the infection site
was measured and recorded on a diagrammatic representation of the
animal.
2.2.3. Biopsy collection
Following sedation, the area of skin for biopsy was cleaned with 4%
w/v chlorhexidine preparation (Hibiscrub, Regent Medical Overseas
Ltd, Manchester, UK) and 1–2 ml of local anaesthetic (lignocaine,
10 mg/ml with adrenaline, 5 μg/ml, Xylocaine, AstraZeneca, Luton UK)
injected subcutaneously in and around the BCG infection site. After
1–2 min, when the skin was fully anaesthetised, a 4 mm biopsy was
collected using a disposable biopsy punch (William Needham &
Associates, Duﬃeld, UK), the piece of skin collected was transferred
into a sterile cryovial and snap frozen. Following sample collection,
pressure was applied to the skin with a gauze swab for 30 s–1 min and
the site cleaned with a moist swab.
2.2.4. Necropsy
Animals were anaesthetised, clinical parameters measured and skin
biopsy collected from the site of BCG infection. The level of anaesthesia
was deepened and blood samples were taken, prior to termination by
intra-cardiac injection of a lethal dose of pentobarbitone sodium
(Dolelethal, Vétoquinol UK Ltd, 140 mg/kg). A full necropsy was per-
formed immediately, gross pathology assessed and the left and right
axillary lymph nodes were collected and snap frozen.
2.3. Infection studies
A summary of the BCG infection studies performed is presented in
Table 1.
2.3.1. Study 1: evaluation of initial human BCG infection model in NHPs
Twelve rhesus macaques were used to compare BCG-vaccinated and
BCG-naïve animals with a study design successfully used in the early
clinical trials of the BCG infection model in humans [16,17]. Six ani-
mals received a BCG vaccination and 21 weeks later all 12 were in-
fected intradermally with a standard dose of BCG. Twenty-one weeks is
the standard interval used in M.tb challenge studies [28,29] and
therefore was chosen for this work. Fourteen days later, a biopsy of the
infection site was taken and BCG quantiﬁed by culture on solid agar and
quantitative polymerase chain reaction (qPCR).
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2.3.2. Study 2: development of the NHP BCG infection model
Both studies 2 and 3 were designed for the purpose of developing
the BCG infection model further in NHPs. In study 2, thirty-two, BCG-
naïve cynomolgus macaques were used for a comparison of BCG in-
fection dose. Sixteen were infected with standard dose BCG and 16 were
infected with high dose BCG. After 14 days, a skin biopsy of the in-
fection site and draining axillary lymph nodes were harvested from
eight animals from the standard dose group and eight animals from the
high dose group. Biopsies and axillary lymph nodes were harvested 28
days post-infection from the remaining eight animals per group.
2.3.3. Study 3: evaluation of the NHP BCG infection model
Using the optimal dose and time interval derived from Study 2,
eight cynomolgus and six rhesus macaques received a BCG vaccination
and 21 weeks later were infected intradermally with high dose BCG,
along with seven BCG-naïve cynomolgus and six BCG-naïve rhesus
macaques. Skin biopsies and axillary lymph nodes were taken 14 days
post-infection.
2.4. Biopsy homogenisation and culture
Biopsies and axillary lymph nodes were processed as previously
described [17,19]. Brieﬂy, samples were thawed and transferred to a
dispomix tube (MACS) containing 1 ml sterile phosphate buﬀered saline
(PBS). Tubes were loaded onto a dispomix machine (Thistle Scientiﬁc)
and homogenised. The homogenate was then sonicated for 15 s. 100 μl
neat homogenate and 100 μl of a 10−1 dilution in PBS, were plated in
triplicate onto Middlebrook 7H11 agar (Appleton Woods Ltd.). Plates
were incubated at 37 °C for 4 weeks before counting of colonies. The
remaining biopsy or lymph node homogenate was stored at−80 °C for
later DNA extraction.
2.5. DNA extraction
Biopsy or lymph node homogenate was thawed and BCG DNA from
200 μl homogenate was released using the tough micro-organism lysing
kit (Precellys®) in a Precellys®24 machine at 6500 rpm for 3 × 30 s.
Sample was transferred to a separate tube and 50 μl PBS used to wash
remaining homogenate from the beads. Samples were then processed as
previously described [19] and DNA was eluted in 400 μl AE buﬀer.
2.6. Quantitative polymerase chain reaction
Primers ET 1/3 (Forward - CCG CCG ACC GAC CTG ACG AC,
Reverse - GGC GAT CTG GCG GTT TGG GG) modiﬁed by Minassian
et al., were used for detection of BCG DNA. These are complementary to
regions ﬂanking the BCG deletion sequence, RD-1 and amplify a 196 bp
fragment [30]. PCR reactions were carried out as previously described
[19]. A standard curve was obtained by extracting BCG DNA from 1 in
10 serial dilutions of 5 pooled SSI vaccine vials in PBS and correcting
for live BCG from the corresponding CFU counts on solid agar.
2.7. Statistical analysis
Statistical analyses were performed using GraphPad Prism. Data was
not normally distributed, so one-way ANOVA (Kruskal-Wallis) and
Mann Whitney U-tests were used to determine signiﬁcant diﬀerences
between groups. The Spearman's Rho test was used to determine cor-
relations between amount of BCG recovered by culture and qPCR.
3. Results
3.1. Quantiﬁcation of BCG from skin biopsies did not detect a diﬀerence
between BCG-vaccinated and BCG-naïve rhesus macaques following
infection with a standard dose of BCG
BCG was detected from skin biopsies of the infection site in 5 out of
6 previously BCG-vaccinated and 4 out of 6 BCG-naïve rhesus macaques
from study 1, by both culture on solid agar and qPCR (Fig. 1). Neither
method of quantiﬁcation detected a signiﬁcant diﬀerence in the amount
of BCG recovered between the two groups. The amount of BCG quan-
tiﬁed from each biopsy was very low, with a median of 32 CFU/biopsy
(range 0–1663), detected across the two groups by solid culture and
317 BCG copy number/biopsy (range 0–6268) by qPCR. BCG was un-
detected, by both culture and qPCR, in 25% (3/12) of NHP biopsies in
this study, however, as only part of the sample was plated out and used
for qPCR, there is a small possibility that these values might not be true
0s.
3.2. Infection with high dose BCG and 14 day sampling interval chosen for
further studies
Comparison of the numbers of BCG CFU recovered from skin
biopsies of cynomolgus macaques, infected with standard and high dose
BCG and sampled at 14 or 28 days post-infection (Study 2), showed no
diﬀerence between the groups (Fig. 2A). Quantiﬁcation of BCG from the
draining axillary lymph nodes detected signiﬁcantly higher numbers of
BCG CFU in both of the high dose groups compared to the standard dose
group who were sampled at 28 days post-infection (Fig. 2B) (Mann
Whitney, p < 0.05). However lymph node data was not available for
two animals in the standard dose group and one animal in the high dose
group (all of which were sampled at day 28) due to contamination on
the agar plates. Sampling at 14 or 28 days post-infection did not appear
to have an eﬀect on the amount of BCG recovered from the lymph nodes
as statistical diﬀerences between the two standard dose groups or the
two high dose groups were not seen (Mann Whitney, p > 0.05).
Therefore, to be consistent with the human infection model, the 14 day
sampling interval was chosen for study 3 with animals infected with
high dose BCG.
3.3. Amount of BCG detected in draining axillary lymph nodes are lower in
previously BCG-vaccinated cynomolgus macaques
Infection with high dose BCG did not result in a signiﬁcant diﬀer-
ence in the number of BCG CFU recovered from the skin biopsies of
Table 1
Summary of NHP BCG infection studies.
Study NHP species Number in study BCG vaccinated (n) BCG naïve (n) Challenge dose Time to sampling (days) Samples taken
1 Rhesus 12 6 6 Standard 14 SB
2 Cynomolgus 32 0 8 Standard 14 SB + LN
0 8 High 14 SB + LN
0 8 Standard 28 SB + LN
0 8 High 28 SB + LN
3 Cynomolgus 15 8 7 High 14 SB + LN
Rhesus 12 6 6 High 14 SB + LN
SB=skin biopsy, LN=lymph node.
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previously BCG-vaccinated and BCG-naïve animals in either the cyno-
molgus (Fig. 3A) or rhesus macaques (Fig. 3C). Quantiﬁcation of BCG
by qPCR also did not result in a signiﬁcant diﬀerence between the
groups (Fig. 3B and D). Quantiﬁcation of BCG CFU from the axillary
lymph nodes draining the site of infection, showed a signiﬁcant re-
duction in the number of BCG CFU detected in the BCG-vaccinated
group compared to the BCG-naïve group in the cynomolgus macaques
(Fig. 3E) (Mann Whitney, p = 0.014). The same was true by quantiﬁ-
cation by qPCR (Fig. 3F) (Mann Whitney, p = 0.0059), In contrast to
the cynomolgus macaques, there was no signiﬁcant diﬀerence in
numbers of BCG CFU detected in the draining axillary lymph nodes of
BCG-vaccinated and BCG-naïve rhesus macaques (Fig. 3G). However,
BCG was undetectable in 2 out of 6 lymph nodes in the BCG-vaccinated
group and 4 out of 6 in the BCG-naïve group, compared to only 1 out of
15 in the cynomolgus macaques. BCG was undetectable by qPCR in all
of the rhesus lymph nodes (Fig. 3H).
Assessment of gross pathology was completely normal for all
animals in these studies.
4. Discussion
We have presented the results of a series of studies to develop and
evaluate an NHP BCG infection model.
Quantiﬁcation of BCG from skin biopsies of the infection site was
not able to distinguish between BCG-vaccinated and BCG-naïve groups
of animals after infection with standard or high dose BCG in either
macaque species. This is in contrast to the human BCG infection model
where, in two separate studies in healthy adults, signiﬁcantly lower
levels of BCG were detected in the skin biopsies of the BCG-vaccinated
compared to BCG-naïve groups [16,17]. The lack of a detectable vac-
cine eﬀect from the skin biopsies of NHPs may be due to the lower
amount of BCG recoverable from NHP compared to human skin biopsies
and the higher percentage of biopsies in which BCG was undetectable.
This discrepancy could be due to diﬀerences between humans and
Fig. 1. Amount of BCG recovered from skin
biopsies at the site of infection with standard
dose BCG. Amount of BCG detected by culture on
solid agar (A) and qPCR (B) from BCG-vaccinated
and BCG-naïve rhesus macaques (Study 1) and
correlation between the two methods of detection
(C). Dots represent individual animals, lines show
median values and stars denote signiﬁcance,
*** = p < 0.001 (Spearman Rho).
Fig. 2. Number of BCG CFU recovered after
infection with standard or high dose BCG.
Number of BCG CFU recovered from skin biopsies
(A) and draining axillary lymph nodes (B) of cy-
nomolgus macaques infected with either standard
or high dose BCG and sampled at either 14 or 28
days post-infection (Study 2). Dots represent in-
dividual animals, lines show median values and
stars denote signiﬁcance * = p < 0.05 (Mann
Whitney).
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NHPs in the tissue structure of the biopsy, as macaque skin possesses
less underlying fatty tissue than human skin, which may impact on BCG
retention at the site, allowing dispersal from the infection site at a faster
rate in NHPs than in humans.
In cynomolgus macaques, quantifying BCG from the axillary lymph
nodes draining the site of infection can distinguish between the BCG
vaccination status of the groups, with signiﬁcantly lower levels of de-
tection in previously BCG-vaccinated animals in a high dose infection
model. The same was not true in rhesus macaques where BCG was
detected in only 50% of the lymph nodes, suggesting that in this
Fig. 3. Number of BCG CFU recovered in cy-
nomolgus and rhesus macaques after infection
with high dose BCG. Number of BCG CFU or BCG
copy number recovered from skin biopsies (A–D)
and axillary lymph nodes (E–H) of cynomolgus
(A, B, E and F) and rhesus macaques (C, D, G and
H) 14 days post-infection with high dose BCG
(Study 3). Dots represent individual animals, lines
show median responses and stars denote sig-
niﬁcance, * = p < 0.05, ** = p < 0.01 (Mann
Whitney).
S.A. Harris et al. Tuberculosis 108 (2018) 99–105
103
species, BCG does not disseminate so readily from the site of infection
to the lymph nodes, highlighting the diﬀerence between the two NHP
species in their response to BCG vaccination and supporting the ﬁnding
that Mauritian cynomolgus macaques are less able to control M.tb than
rhesus macaques [31]. This also emphasises the importance of char-
acterising the response to BCG andM.tb in both species in more detail in
order to select the most appropriate species to use to model human
disease.
BCG vaccination has been shown to be partially protective against
pulmonary M.tb infection in rhesus [29,32] and cynomolgus [33–35]
macaques. The results presented here from the high dose BCG infection
model in cynomolgus macaques have shown a BCG vaccine eﬀect si-
milar to the partial protection seen with aerosol M.tb infection, as BCG
growth was reduced in the BCG-vaccinated compared to the BCG-naïve
group. These data provide important evidence to support the human
infection model as it is not possible to validate against M.tb infection in
humans. Demonstration of a BCG vaccine eﬀect in rhesus macaques
may be achievable after further development of the model. The ulti-
mate validation of this model in NHPs would be to follow ID BCG in-
fection with aerosolM.tb challenge and assess whether the results of the
BCG infection are predictive of the outcome of the M.tb challenge.
However, as the detectable vaccine eﬀect was observed in the lymph
nodes, this requires necropsy and therefore the same animals cannot go
on to receive aerosol M.tb.
Models such this could also be used to help identify immune cor-
relates of mycobacterial immunity, which could be targeted in further
vaccine development. Peripheral blood mononuclear cells and serum
samples from these studies have been cryopreserved and will be used to
investigate cellular and humoral immune responses and perform my-
cobacterial growth inhibition assays (MGIAs) to assess correlations with
the BCG infection outcome. This in turn will provide biological vali-
dation of the putative correlates such as MGIA, which may also have
utility as an additional alternative to using virulent pre-clinical M.tb
infection models to evaluate the eﬃcacy of candidate TB vaccines.
Although an ID BCG infection model appears to be a valid surrogate
for aerosol M.tb infection, there are some limitations. The natural route
of M.tb infection is by aerosol. The aerosol delivery of BCG has been
shown to be safe, immunogenic [36] and protective [37] in rhesus
macaques and a clinical trial is currently ongoing in humans to assess
aerosol BCG as a route of delivery, both as a potential route of vacci-
nation and as a potential route of challenge in a controlled human in-
fection model (clinicaltrials.gov ref. NCT02709278). Unlike M.tb and
M.bovis, the genome of BCG does not possess the RD-1 region, which
encodes the secretory proteins ESAT-6 and CFP-10, both important
virulence factors [38]. Therefore, the eﬃcacy of candidate vaccines
which include these antigens may not be fully evaluated using this BCG
infection model. However, an attenuated strain of M.tb, MTBVAC, is
currently in phase 1 clinical trials [39] and such a strain could be
considered for use in future controlled human infection models.
An infection model using BCG or an attenuated strain of M.tb would
be a less severe way of testing new TB vaccines in NHPs and would
comply with the NC3Rs criteria of improving the welfare of the animals
as it would remove the requirement for animals to be exposed to
virulent M.tb and to develop clinical signs of TB disease. They would
also have a better quality of life as do not need to be conﬁned to BSL3
facilities and therefore would beneﬁt from a richer housing environ-
ment [25]. Furthermore, removing the expensive and restrictive BSL3
facilities needed for M.tb infection would increase the number of sites
able to perform such studies and would be a more cost-eﬀective, easier
and potentially more high-throughput way of screening new TB vac-
cines. Both the NHP and human BCG infection models could provide a
useful tool in TB vaccine development and aid in discovering and va-
lidating immunological correlates of protection.
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